Needham & Company LLC Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Key Points

• Needham cut its Hims & Hers price target from $42 to $32 but maintained a Buy rating; the new target implied 39.76% upside from the prior close.
• Analyst views overall were more cautious: the stock had a consensus Hold rating and an average price target of $31.77, with 3 Buy, 11 Hold, and 1 Sell ratings.
• Shares were reported down 11.9%. In its latest cited quarterly results, the company missed EPS expectations but beat revenue estimates, with revenue up 38.2% year over year.

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its target price lowered by equities researchers at Needham & Company LLC from $42.00 to $32.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price target would indicate a potential upside of 39.76% from the company's previous close.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley lifted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 11th. Weiss Ratings reissued a "sell (d)" rating on shares of Hims & Hers Health in a report on Wednesday, November 4th. Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Barclays decreased their price target on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a report on Friday, August 21st. Finally, Citigroup decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $31.77.

Hims & Hers Health Stock Down 11.9%

Shares of Hims & Hers Health stock opened at $22.90 on Tuesday. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $42.70. The company has a 50 day moving average of $28.31 and a 200 day moving average of $26.91. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The company has a market capitalization of $5.34 billion, a P/E ratio of -36.34 and a beta of 2.53.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same quarter last year, the firm earned $0.17 EPS. The company's revenue was up 38.2% on a year-over-year basis. As a group, research analysts forecast that Hims & Hers Health will post -0.16 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah Autor sold 16,773 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares in the company, valued at $1,363,563.85. This represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 29,277 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total value of $876,846.15. Following the completion of the sale, the chief financial officer directly owned 236,527 shares of the company's stock, valued at approximately $7,083,983.65. This trade represents a 11.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 133,905 shares of company stock worth $3,826,977. Corporate insiders own 11.76% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Jean Financial LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $3,159,000. B. Metzler seel. Sohn & Co. AG purchased a new position in Hims & Hers Health in the second quarter valued at about $2,992,000. FirstWave Capital Management LLC increased its holdings in Hims & Hers Health by 30.6% in the second quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company's stock valued at $11,787,000 after buying an additional 79,731 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of Hims & Hers Health by 109.8% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company's stock valued at $1,223,000 after acquiring an additional 18,459 shares during the period. Finally, Bienville Capital Management LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at approximately $27,242,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Third-quarter revenue rose about 49% year over year to $890.4 million, while the subscriber base remained substantial at 2.8 million. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Neuroscientist and popular health educator Andrew Huberman joined the board. His profile could support the company’s brand, though the appointment’s financial impact is not yet clear. Article: Dr. Andrew Huberman Joins Hims & Hers Board of Directors
• Negative Sentiment: Adjusted earnings were $0.03 per share, below estimates of roughly $0.06–$0.07, and revenue of $890.4 million narrowly missed the $893.1 million consensus. The company also narrowed its 2026 revenue outlook, with climbing costs and contracting margins weighing on its profit forecast. These results have extended the stock’s recent weakness. Article: Hims & Hers narrows 2026 revenue forecast as margins contract
• Negative Sentiment: Subscriber numbers reached 2.8 million but fell by 100,000 on a net basis, raising questions about customer growth alongside the weaker outlook. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.